Five years ago I was lucky enough to be involved in a project that resulted in publications about the then current state of the art treatments for lipid-lowering treatments [1] and the potential for the proprotein convertase subtilisin/kexin type 9 (PCSK9) axis for the treatment of hyperlipidaemia [2]. Today, over 300 people have looked at the first paper on ResearchGate. Cutting down on lipids has been shown to help lower cholesterol and its related problems. The development of atherosclerosis, which leads to coronary heart disease (CHD), stroke, and peripheral vascular disease like carotid and femoral artery stenosis, is linked to a number of risk factors for CVD, such as high cholesterol.
Statins were the mainstay of care and had done a huge amount of good for society by lowering the number of cases of atherosclerotic heart disease, but they still can't treat all parts of dyslipidaemia. Even though they were widely used, atherosclerotic cardiovascular disease was and still is the world's top cause of death.
Innovations in technology, like those in genetics, have changed the way drugs are found and made. A lot of new therapeutic substances are being made. There are more medicines for lowering bad cholesterol, like thyroid mimetics (thyroid receptor beta-agonists), antisense oligonucleotides, or microsomal transfer protein inhibitors (MTPI); lowering triglycerides, like novel peroxosimal proliferator activating receptors agonists, MTPIs, diacylglycerol acyl transferase-1 inhibitors; and lowering high-density lipoprotein cholesterol (HDL-C), like mimetic peptides; HDL delipidation strategies and cholesterol ester transfer protein inhibitors; and controlling inflammation, like phospholipase inhibitors.
Therapeutically lowering LDL-C can help stop fatty cardiovascular disease, and the size of the effect depends on how much LDL-C is lowered and how long it is exposed to the drug. This new information backs up the idea that lowering long-term LDL-C risk should be a main goal of therapy. By blocking PCSK9 with monoclonal antibodies, LDL-C levels could be lowered to very low levels.
New therapeutic platforms, like RNA inhibition, make it possible to combine strong lipid-lowering with dosing schedules that aren't repeated often. This makes medicines that work like vaccines possible. In clinical studies, alipogene tiparvovec has also been used for gene therapy to treat some rare disorders, such as lipoprotein lipase deficiency. In 2012, we said that lipid-lowering drugs are likely to continue to be an area of fast growth for new treatments because new and old chemicals may work together to treat atherosclerosis. Interest continues 5 years later, we will soon be hearing about the therapeutic potential of lipid-lowering therapies with targets other than LDL-C, such as Lp(a) [lipoprotein(a)], TRL (triglyceride-rich lipoproteins), and remnant cholesterol currently being investigated in on-going clinical trials. The available evidence suggests that reducing Lp(a) or TRLs could attenuate atherosclerotic cardiovascular disease risk in specific categories of patients.
References
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
I've been studying medicine for 40 years, and it's beginning to look like something out of science fiction
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Paraskevidekatriaphobia is a phobia of Friday the 13th. Yes, they actually gave it a name.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
In the past, Halloween has meant the end of the crop and the start of the dark, cold winter.
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Yes, it’s Star Wars Day again! The Star Wars films base their wow-factor on their adoption of science
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Congratulations class of 2024. That was all I needed to hear when I stood in your shoes almost 40 years ago. 40 years
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Finding the best vehicle in which to publish your research findings is a perennial challenge.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
I have never been great at conferences. People don’t believe me but I am painfully shy and far too worried about what.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
